全文获取类型
收费全文 | 151429篇 |
免费 | 12877篇 |
国内免费 | 4455篇 |
专业分类
耳鼻咽喉 | 1190篇 |
儿科学 | 2649篇 |
妇产科学 | 1994篇 |
基础医学 | 9143篇 |
口腔科学 | 3246篇 |
临床医学 | 19274篇 |
内科学 | 22068篇 |
皮肤病学 | 2381篇 |
神经病学 | 12597篇 |
特种医学 | 9689篇 |
外国民族医学 | 51篇 |
外科学 | 14132篇 |
综合类 | 21557篇 |
现状与发展 | 24篇 |
一般理论 | 2篇 |
预防医学 | 5663篇 |
眼科学 | 2354篇 |
药学 | 11046篇 |
80篇 | |
中国医学 | 11279篇 |
肿瘤学 | 18342篇 |
出版年
2024年 | 160篇 |
2023年 | 2777篇 |
2022年 | 4053篇 |
2021年 | 6754篇 |
2020年 | 6765篇 |
2019年 | 6186篇 |
2018年 | 5626篇 |
2017年 | 6181篇 |
2016年 | 6395篇 |
2015年 | 6121篇 |
2014年 | 10972篇 |
2013年 | 13182篇 |
2012年 | 8875篇 |
2011年 | 9529篇 |
2010年 | 7856篇 |
2009年 | 7374篇 |
2008年 | 7206篇 |
2007年 | 7564篇 |
2006年 | 6877篇 |
2005年 | 6120篇 |
2004年 | 4912篇 |
2003年 | 4466篇 |
2002年 | 3745篇 |
2001年 | 3222篇 |
2000年 | 2540篇 |
1999年 | 1986篇 |
1998年 | 1586篇 |
1997年 | 1349篇 |
1996年 | 1157篇 |
1995年 | 1139篇 |
1994年 | 933篇 |
1993年 | 702篇 |
1992年 | 581篇 |
1991年 | 525篇 |
1990年 | 432篇 |
1989年 | 387篇 |
1988年 | 368篇 |
1987年 | 309篇 |
1986年 | 244篇 |
1985年 | 290篇 |
1984年 | 248篇 |
1983年 | 186篇 |
1982年 | 182篇 |
1981年 | 171篇 |
1980年 | 139篇 |
1979年 | 130篇 |
1978年 | 70篇 |
1977年 | 44篇 |
1976年 | 53篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
31.
《Journal of the American Medical Directors Association》2022,23(3):379-386.e3
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD. 相似文献
32.
33.
34.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
35.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
36.
37.
BackgroundGlioma accounts for most central nervous system tumors, and the degree of invasion and malignancy are higher in the recurrent glioma. Photodynamic therapy (PDT) is an effective strategy in glioma. This study aimed to explore the risk factors for re-recurrence after a second glioma surgery and the effects of PDT on re-recurrence.MethodsThis was a retrospective study in the Second Affiliated Hospital of Harbin Medical University in China, and 43 patients that received the secondary surgery for recurrent glioma were included. The Kaplan-Meier test and Cox proportional hazard method were used to analyze.ResultsThe total re-recurrence rate after the second surgery for recurrent glioma was 48.84%. When the age increased by 1, the risk of re-recurrence increased 1.065 times (95% CI 1.000–1.134, P = 0.049). High matrix metalloproteinase (MMP) 2 expression was associated with a significantly higher risk of re-recurrence than low MMP2 expression (HR = 25.550, 95% CI 3.190–204.650, P = 0.002). Pathological grades IV and III were associated with a significantly higher risk of re-recurrence than pathological grade II (HR = 17.121, 95% CI 2.345–124.986, P = 0.005; HR = 2863.470, 95% CI 100.697–81,427.197, P < 0.001). PDT decreased the risk of re-recurrence (HR = 25.550, 95% CI 3.190–204.650, P = 0.002) and increased survival time (HR = 3.611, 95% CI 1.012–12.888, P = 0.048).ConclusionThe age, MMP2 expression, and pathological grade are independent risk factors for re-recurrence after a second surgery for recurrent glioma. PDT during the second surgery decreased the risk of re-recurrence and increased survival time. 相似文献
38.
39.
40.